StockNews.AI
TVTX
StockNews.AI
10 hrs

Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy

1. FDA approves updated REMS labeling for TVTX's FILSPARI, improving treatment regimen. 2. Liver monitoring frequency reduced, enhancing accessibility for IgAN treatment.

FDA Approval
0%Current Return
VS
0%S&P 500
$17.4408/27 05:25 PM EDTEvent Start
$17.4408/28 02:58 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

FDA approval typically boosts stock prices. Similar past approvals led to price surges.

How important is it?

FDA approvals can significantly increase investor confidence and market interest in a stock.

Why Short Term?

The immediate impact of FDA approval can increase demand and stock price. Long-term effects depend on market adoption of FILSPARI.

Related Companies

VRTXADPTAMGN
SAN DIEGO--(BUSINESS WIRE)---- $TVTX #IgAN--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for FILSPARI® (sparsentan), the only Dual Endothelin Angiotensin Receptor Antagonist for the treatment of IgA nephropathy (IgAN). The update reduces the frequency of liver function monitoring to every three months from the onset of treatment with FILSPARI and removes the embryo-fetal t.

Related News